期刊文献+

多西他赛与奥沙利铂及替吉奥治疗晚期胃癌的效果

原文传递
导出
摘要 目的研究多西他赛联合奥沙利铂及替吉奥三药治疗晚期胃癌的临床疗效及安全性。方法选择2014年1月-2016年12月江苏省睢宁县人民医院肿瘤内科接收的64例晚期胃癌患者,随机分为对照组和观察组各32例,对照组给予奥沙利铂及替吉奥方案化疗,观察组在对照组的基础上加用多西他赛化疗,分析比较两组化疗方案的临床疗效和不良反应。结果其中观察组脱发、中性粒细胞减少、Ⅰ~Ⅱ级恶心呕吐腹泻、Ⅰ~Ⅱ级周围神经毒性及Ⅰ~Ⅱ级乏力发生率均高于对照组,且差异有统计学意义(P<0.05)。对照组中位PFS为8.9个月,观察组中位PFS为11.2个月,两组比较差异有统计学意义(P<0.05)。对照组中位OS为13.1个月,观察组中位OS为16.8个月,两组比较差异有统计学意义(P<0.05)。结论晚期胃癌患者采用多西他赛联合奥沙利铂及替吉奥三药方案疗效较好,副反应可耐受,值得扩大样本量进一步研究。
作者 黄芳
出处 《中国城乡企业卫生》 2019年第6期173-176,共4页 Chinese Journal of Urban and Rural Enterprise Hygiene
  • 相关文献

二级参考文献47

  • 1胃癌诊疗规范(2011年版)[J].中国医学前沿杂志(电子版),2012,4(5):62-71. 被引量:244
  • 2Cunningham D,Allum WH,Stenning SP,菅鑫妍.手术期间化学疗法与单独手术治疗可切除的胃食管癌疗效比较[J].中国处方药,2006,5(8):59-60. 被引量:434
  • 3Shah MA,Janjigian YY,Stoller R,et al.Randomized Multicenter Phase II Study of Modified Docetaxel,Cisplatin,and Fluorouracil(DCF)Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma:A Study of the US Gastric Cancer Consortium[J].J Clin Oncol,2015,33(33):3874-3879.
  • 4Feng ZL,Chen LB,Liu ZY,et al.DCF intraperitoneal and intravenous dual chemotherapy regimen for advanced gastric cancer:A feasibility study[J].Oncol Lett,2015,9(1):491-497.
  • 5Van Cutsem E,Boni C,Tabernero J,et al.Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer:a randomized phase II study[J].Ann Oncol,2015,26(1):149-156.
  • 6Teker F,Yilmaz B,Kemal Y,et al.Efficacy and safety of docetaxel or epirubicin,combined with cisplatin and fluorouracil(DCF and ECF),regimens as first line chemotherapy for advanced gastric cancer:a retrospective analysis from Turkey[J].Asian Pac J Cancer Prev,2014,15(16):6727-6732.
  • 7Dong L,Li J,Lou XP,et al.Comparison of short-term efficacy and safety of TIROX and DCF regimens for advanced gastric cancer[J].J Int Med Res,2014,42(3):737-743.
  • 8Liu Y,Feng Y,Gao Y,et al.Clinical benefits of combined chemotherapy with S-1,oxaliplatin,and docetaxel in advanced gastric cancer patients with palliative surgery[J].Onco Targets Ther,2016,7(9):1269-1273.
  • 9Guo M,Yu Y,Wang Y,et al.Low-dosed docetaxel showed equivalent efficacy but improved tolerability compared with oxaliplatin in the S-1-based first-line chemotherapy regimen for metastatic or recurrent gastric adenocarcinoma[J].Med Oncol,2015,32(9):230.
  • 10Kim HS,Ryu MH,Zang DY,et al.Phase II study of docetaxel,oxaliplatin,and S-1therapy in patients with metastatic gastric cancer[J].Gastric Cancer,2016,19(2):579-585.

共引文献164

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部